Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2011 Apr;96(4):488-91.
doi: 10.3324/haematol.2011.041988.

The rationale for using hydroxycarbamide in the treatment of sickle cell disease

David C Rees
Editorial

The rationale for using hydroxycarbamide in the treatment of sickle cell disease

David C Rees. Haematologica. 2011 Apr.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Diagram showing three independent actions of hydroxycarbamide which are potentially of therapeutic benefit in preventing vaso-occlusion and vasculopathy. Most evidence exists for hydroxycarbamide’s action on erythroid cells (thick arrow), while observational studies have suggested that the reduced neutrophil count is also of therapeutic benefit (thin arrow). Laurance et al. in this issue showed in vitro evidence of hydroxycarbamide altering adhesion molecule expression in the vascular endothelium (dotted arrow) although the clinical significance of this is not yet known.
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Dresler WFC, Stein R. Ueber den Hydroxylharnstoff. Justus Liebigs Ann Chemie. 1869;150:1317–22.
    1. Rosenthal F, Wislicki L, Kollek L. Uber die Bezeihungen von schwersten Blutgiften zu Abbauprodukten des Eiweisses. Ein Beitrag zum Entstehungsmecanismus der perniziosen Anamie. Klin Wochenschr. 1928;7:972–7.
    1. Stearns B, Losee KA, Bernstein J. Hydroxyurea. A new type of potential antitumor agent. J Med Chem. 1963;6:201. - PubMed
    1. Kennedy BJ, Yarbro JW. Metabolic and therapeutic effects of hydroxyurea in chronic myelogenous leukemia. Trans Assoc Am Physicians. 1965;78:391–9. - PubMed
    1. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376(9757):2018–31. - PubMed

MeSH terms